IL 13 Variant Human
Interleukin-13 Variant Human Recombinant
Cat. No.
BT30794
Source
Escherichia Coli.
Synonyms
Interleukin-13, NC30, ALRH, BHR1, P600, IL-13, MGC116786, MGC116788, MGC116789.
Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Purity
Greater than 95% as determined by(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
(b) Analysis by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs 
In Stock 
Description
Interleukin-13 Variant Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 114 amino acids, with a substitution of Q for R at position 112 compared with the wild type IL-13, having a molecular mass of 12.5 kDa.
The IL-13 Variant is purified by proprietary chromatographic techniques.
The IL-13 Variant is purified by proprietary chromatographic techniques.
Product Specs
Introduction
Interleukin 13 (IL-13) is a regulatory cytokine primarily secreted by activated T helper 2 (Th2) cells. This protein plays a crucial role in B cell development, influencing their maturation and differentiation. IL-13 increases the expression of CD23 and MHC class II molecules on B cells, promoting their ability to present antigens to T cells. Additionally, it stimulates B cells to switch their antibody production to the IgE isotype, which is associated with allergic responses. IL-13 also exhibits anti-inflammatory effects by suppressing macrophage activity, thereby reducing the release of pro-inflammatory cytokines and chemokines. These molecules play a significant role in the development of allergic asthma, though the underlying mechanisms are independent of IgE and eosinophils. Notably, the genes encoding IL-13 (IL13), IL3, IL5, IL4, and CSF2 are clustered together on chromosome 5q, with IL13 located in close proximity to IL4.
Description
Recombinant human interleukin-13 variant is a single-chain polypeptide produced in E. Coli. This non-glycosylated protein consists of 114 amino acids and has a molecular weight of 12.5 kDa. The variant form differs from wild-type IL-13 by a single amino acid substitution at position 112, where arginine is replaced with glutamine (R112Q). Purification of the IL-13 variant is achieved using proprietary chromatographic techniques.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
The protein was lyophilized from a 0.2 μm filtered solution in 1x phosphate-buffered saline (PBS) at pH 7.2, containing 5% trehalose.
Solubility
To reconstitute the lyophilized interleukin-13 variant, it is recommended to dissolve the powder in sterile 18 MΩ-cm H2O to a concentration of at least 100 μg/ml. This solution can then be further diluted in other aqueous solutions as needed.
Stability
Lyophilized interleukin-13 variant is stable at room temperature for up to 3 weeks. However, for long-term storage, it is recommended to store the lyophilized powder desiccated at or below -18°C. After reconstitution, IL-13 variant should be stored at 4°C for 2-7 days. For extended storage, it is advisable to add a carrier protein such as 0.1% human serum albumin (HSA) or bovine serum albumin (BSA). Avoid repeated freeze-thaw cycles.
Purity
The purity of the protein is greater than 95%, as determined by reverse-phase high-performance liquid chromatography (RP-HPLC) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Biological Activity
The biological activity of the protein was evaluated based on its ability to induce the proliferation of TF-1 cells. The half-maximal effective concentration (ED50) was determined to be less than 1 ng/ml, corresponding to a specific activity greater than 1,000,000 units/mg. Notably, this IL-13 variant exhibits enhanced in vivo activity compared to wild-type IL-13.
Synonyms
Interleukin-13, NC30, ALRH, BHR1, P600, IL-13, MGC116786, MGC116788, MGC116789.
Source
Escherichia Coli.
Amino Acid Sequence
SPGPVPPSTA LRELIEELVN ITQNQKAPLC NGSMVWSINL TAGMYCAALE SLINVSGCSA IEKTQRMLSG FCPHKVSAGQ FSSLHVRDTK IEVAQFVKDL LLHLKKLFRE GQFN.
Product Science Overview
Introduction
Interleukin-13 (IL-13) is a cytokine produced primarily by T-helper type 2 (Th2) cells. It plays a crucial role in the immune system, particularly in the regulation of inflammatory and immune responses. The recombinant variant of human IL-13 is a laboratory-produced version of this cytokine, designed to mimic its natural counterpart.
Structure and Production
The human IL-13 gene is located on chromosome 5q31 and consists of four exons and three introns . Recombinant human IL-13 is typically expressed in Escherichia coli (E. coli) and is purified to high levels of purity, often exceeding 98% as determined by SDS-PAGE and HPLC . The recombinant protein has a molecular weight of approximately 12.5 kDa and consists of 114 amino acid residues .
Biological Functions
IL-13 is involved in various biological processes, including:
- Immune Regulation: IL-13 stimulates the proliferation of B cells and the production of immunoglobulins . It also plays a role in the differentiation of monocytes into macrophages .
- Parasitic Infections: IL-13 is upregulated during parasitic infections and contributes to the host’s protective immunity. It promotes eosinophil activation and the expulsion of parasites through increased intestinal contractility .
- Airway Disorders: In conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, IL-13 promotes the formation of airway goblet cells, leading to excess mucus secretion . This process is regulated by IL-13-activated autophagy .
Clinical Applications
Recombinant IL-13 has been used in various research and clinical applications, including:
- Cell Culture Studies: It is used to treat THP1 monocytes along with IL-4 and phorbol myristate acetate (PMA) to study the differentiation of these cells into M2 macrophages .
- Therapeutic Potential: IL-13 has potential therapeutic applications in treating inflammatory and autoimmune diseases due to its immunoregulatory properties .
Reconstitution and Storage
Recombinant IL-13 is typically lyophilized and requires reconstitution in an appropriate buffer before use. It is recommended to reconstitute the protein in 20 mM acetic acid to a concentration of 0.1-0.5 mg/ml and allow it to sit at 4°C for at least 2 hours before use . For extended storage, the reconstituted solution should be further diluted in a buffer containing a carrier protein, such as 0.1% BSA, and stored in aliquots at -20°C to -80°C .
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
